---
title: Prevalence of Abnormalities in Ultrasonography of Joint and Tendons in Patients With Gout
nct_id: NCT05546593
overall_status: RECRUITING
sponsor: Assistance Publique - Hôpitaux de Paris
study_type: OBSERVATIONAL
primary_condition: Gout
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05546593.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05546593"
ct_last_update_post_date: 2025-03-19
last_seen_at: "2026-05-12T07:26:23.414Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Prevalence of Abnormalities in Ultrasonography of Joint and Tendons in Patients With Gout

**NCT ID:** [NCT05546593](https://clinicaltrials.gov/study/NCT05546593)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** Assistance Publique - Hôpitaux de Paris
- **Conditions:** Gout
- **Start Date:** 2022-08-24
- **Completion Date:** 2026-04
- **CT.gov Last Update:** 2025-03-19

## Brief Summary

Gout is the most frequent inflammatory arthritis in men after 40 years, with a prevalence of 0.9% in France. This disease is characterized by deposits of sodium urate crystals in joints, tendons and soft tissues, which can be detected by ultrasound examination. To date, there was no study assessing inflammatory, structural and deposit lesions due to gout in joints and tendons, since the standardization of ultrasound definitions of gout by the OMERACT (Outcome Measures in Rheumatology) in 2015. The objective of this study is t estimate the prevalence and severity of ultrasound inflammatory lesions (synovitis, tenosynovitis, soft tissues abnormalities), structural lesions (osteophytes, erosions) and abnormalities due to sodium urate deposits (double contour, aggregates, tophi) in patients with gout.

## Detailed Description

Gout is the most frequent inflammatory arthritis in men after 40 years, with a prevalence of 0.9% in France. This disease is characterized by deposits of sodium urate crystals in joints, tendons and soft tissues, which can be detected by ultrasound examination. To date, there was no study assessing inflammatory, structural and deposit lesions due to gout in joints and tendons, since the standardization of ultrasound definitions of gout by the OMERACT (Outcome Measures in Rheumatology) in 2015. The objective of this study is t estimate the prevalence and severity of ultrasound inflammatory lesions (synovitis, tenosynovitis, soft tissues abnormalities), structural lesions (osteophytes, erosions) and abnormalities due to sodium urate deposits (double contour, aggregates, tophi) in patients with gout. This is a transversal bicentric study, including patients who consulted for gout in the Rheumatology and Internal Medicine department of Ambroise Paré Hospital. Inclusion criteria were adult patients with a diagnosis of gout according to ACR/EULAR 2015 criteria and able to give informed consent. Exclusion criteria were the presence of other chronic inflammatory rheumatic diseases and patients without French social insurance. Patients had clinical and ultrasound examination, realized by two physicians blinded from each other.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

Inclusion criteria were adult patients with a diagnosis of gout according to ACR/EULAR 2015 criteria and able to give informed consent. Exclusion criteria were the presence of other chronic inflammatory rheumatic diseases and patients without French social insurance.

Exclusion Criteria:

\-
```

## Primary Outcomes

- **Ultrasound lesion of gout as defined by OMERACT (Outcome Measures in Rheumatology)** _(time frame: at baseline)_ — double contour, agreggates, tophi, erosions, synovitis, tenosynovitis and osteophytes

## Locations (1)

- Rhumatology department, Ambroise Paré hospital - APHP, Boulogne-Billancourt, APHP, France — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.rhumatology department, ambroise paré hospital - aphp|boulogne-billancourt|aphp|france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05546593.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05546593*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*